ClinicalTrials.gg
RecruitingNCT06833372SWinKAUpdated Oct 30, 2026

Shock Waves in Knee Arthritis

An interventional study of ESWT group and exercise group in Arthritis of Knee, sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari. Recruiting at 1 site in Italy. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Study summary

Pathological arthritis is a degenerative disease affecting the joints, characterized by pain, limitation of movement up to ankylosis and disability. Treatment is aimed at reducing pain and slowing the loss of functionality of the district. Among conservative treatments, pharmacological options (NSAIDs, cortisone, contrasupplements, hyaluronic acid) and non-pharmacological options (therapeutic exercise, physical therapy, orthosis, etc.) are indicated. In cases not responding to conservative treatments, surgical treatment will be necessary with prosthetic replacement of the joint district.

Read the detailed description

In recent years, shock wave therapy has received a lot of interest in the treatment of numerous musculoskeletal pathologies. This physical therapy exploits the cavitational effect induced on the tissues which translates into neo-angiogenic, anti-inflammatory, regenerative and analgesic action. Until now, the indication has been reserved for the treatment of tendinopathies and delayed consolidation of fractures. Pre-clinical research is also paving the way for the treatment of cartilage pathologies; in fact, after the stimulation of the chondrocyte, a modulation of the phlogogenic cytokines has been found, supporting a slowing down of the progression of the arthritic pathology. The first clinical experiences on arthritic models, such as rhizarthrosis, allow to support the indication also on the pathological model of gonarthrosis. The aim of this study is to verify the effects of shock wave therapy in the patient affected by gonarthrosis, monitoring the action on pain, functionality and tissue district changes.

02

Conditions studied

  • Arthritis of Knee

Keywords

  • shock waves
  • conservative treatment
03

In context

Lead sponsor

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari is the lead sponsor of 47 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • persistent knee pain for at least 3 months, measured with a VAS scale of 4 or higher,
  • clinical and radiological diagnosis confirming knee osteoarthritis grade 2 and 3 based on the Kellgren-Lawrence system,
  • no history of physical therapy in the last 3 months,
  • no infections, tumors in the treatment area of the knee,
  • no pathology other than osteoarthritis that could cause knee pain,
  • no pathology of the lumbar spine or hip that could refer knee pain,
  • free from any condition that prevents participation in exercise or physical therapy willing to participate regularly in the treatment programs were included in the study.

Exclusion criteria

Exclusion Criteria:

  • inability to walk,
  • a history of clinically symptomatic spinal stenosis or lumbar radiculopathy,
  • evidence of a neurological disorder based on history or physical examination,
  • generalized pain or fibromyalgia,
  • secondary osteoarthritis (to metabolic or rheumatologic disease),
  • administration of intra-articular injections (anesthetic, hyaluronic acid, cortisone) of the knee in the last 6 months,
  • use of NSAIDs, paracetamol or topical agents in the previous week,
  • a previous history of surgery involving the knee joint,
  • to physical therapy (PM, epilepsy, neoplasia, coagulopathy, pregnancy).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    Exercise Group

    only a daily exercise program for 4 weeks: passive and active assisted movement of the knee joint, hamstring stretching, and quadriceps strengthening exercises

    Other: exercise group

  • Experimental
    ESWT group

    Shockwave therapy will be administered using an ESWT device (Minilith SL1, Storz) once a week for three consecutive weeks, for a total of three sessions. A focused shockwave modality with an electromagnetic device was chosen for the therapy.

    Device: ESWT group

Interventions

  • DeviceESWT group

    During each session, participants will receive 2000 pulses at a frequency of 4 Hz and an EDF between 0.02 and 0.2 mJ/mm2.

    Also known as: shock waves therapy

  • Otherexercise group

    daily exercise program

    Also known as: exercise

06

What researchers measure

Primary outcomes

  1. recovery of pain

    The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."

    Time frame: From enrollment to 1, 3 and 6 months

  2. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    questionnaire consisting of 24 questions addressing pain, stiffness and physical function. Score from 0 to 96, higher scores correspond to worse clinical condition.

    Time frame: From enrollment to 1, 3 and 6 months

Secondary outcomes

  1. Roles and Maudsley Score

    rating of the perception of one's own clinical improvement, from 1 (excellent) to 4 (poor).

    Time frame: At 1, 3 and 6 months

  2. MR image

    weighted in t2 according to the ICRS classification

    Time frame: From enrollment to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zhao Z, Ji H, Jing R, Liu C, Wang M, Zhai L, Bai X, Xing G. Extracorporeal shock-wave therapy reduces progression of knee osteoarthritis in rabbits by reducing nitric oxide level and chondrocyte apoptosis. Arch Orthop Trauma Surg. 2012 Nov;132(11):1547-53. doi: 10.1007/s00402-012-1586-4. Epub 2012 Jul 24. PubMed 22825641 ↗
  • Ochiai N, Ohtori S, Sasho T, Nakagawa K, Takahashi K, Takahashi N, Murata R, Takahashi K, Moriya H, Wada Y, Saisu T. Extracorporeal shock wave therapy improves motor dysfunction and pain originating from knee osteoarthritis in rats. Osteoarthritis Cartilage. 2007 Sep;15(9):1093-6. doi: 10.1016/j.joca.2007.03.011. Epub 2007 Apr 26. PubMed 17466542 ↗
  • Mostafa MSEM, Hamada HA, Kadry AM, Zahran SS, Helmy NA. Effect of High-Power Laser Therapy Versus Shock Wave Therapy on Pain and Function in Knee Osteoarthritis Patients: A Randomized Controlled Trial. Photobiomodul Photomed Laser Surg. 2022 Mar;40(3):198-204. doi: 10.1089/photob.2021.0136. Epub 2022 Jan 5. PubMed 34986012 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 18, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06833372
Lead sponsor
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Oct 1, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Angela Notarnicola, M.D.Ph.D.
Contact
angelanotarnicola@yahoo.it
+39 0805592938
Ilaria Covelli, M.D.Ph.D.
Contact
ilariacovelli@yahoo.it
+ 39 0805592938

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion